Stock Events

Stock Events

Xenon Pharmaceuticals 

€48.8
26
-€1.2-2.4% Thursday 06:16

Statistics

Day High
47.2
Day Low
47.2
52W High
53.5
52W Low
25
Volume
-
Avg. Volume
-
Mkt Cap
3.9B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.31
-1.14
-0.98
-0.81
Expected EPS
-1.181976
Actual EPS
N/A

Financials

-4,457.61%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
13.32MRevenue
-593.95MNet Income

Analyst Ratings

$53.65Average Price Target
The highest estimate is 73.60.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XP0.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for genetic diseases, similar to Xenon's focus on neurological disorders.
Biogen
BIIB
Mkt Cap22.63B
Biogen competes in the neurological disorder space, particularly in developing therapies for diseases like multiple sclerosis and Alzheimer's, overlapping with Xenon's target market.
Alkermes
ALKS
Mkt Cap5.07B
Alkermes competes with Xenon in developing treatments for central nervous system (CNS) disorders, including schizophrenia and bipolar disorder.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals is a competitor due to its focus on RNA-targeted drug discovery for neurological diseases, a similar area of interest as Xenon.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.83B
ACADIA Pharmaceuticals targets the CNS disorder market, with a focus on psychosis and schizophrenia treatments, areas that overlap with Xenon's research interests.
AMGEN
AMGN
Mkt Cap160.66B
Amgen, with its broad focus on biotechnological therapies for various conditions, competes indirectly with Xenon through its investments in neuroscience and neurodegenerative diseases.
PTC Therapeutics
PTCT
Mkt Cap5.4B
PTC Therapeutics operates in the space of rare diseases, including neurological disorders, making it a competitor to Xenon's specialized focus.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing, a technology that has the potential to treat genetic disorders, competing with Xenon's approach to drug development.

About

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Show more...
CEO
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.
Employees
316
Country
CA
ISIN
CA98420N1050
WKN
000A12ETN

Listings

XNAS
US
XENE
F
DE
XP0.F
BOATS
BOATS
XENE.BOATS

0 Comments

Share your thoughts

FAQ

What is Xenon Pharmaceuticals stock price today?▼
The current price of XP0.F is €48.8 EUR — it has decreased by -2.4% in the past 24 hours. Watch Xenon Pharmaceuticals stock price performance more closely on the chart.
What is Xenon Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Xenon Pharmaceuticals stocks are traded under the ticker XP0.F.
Is Xenon Pharmaceuticals stock price growing?▼
XP0.F stock has risen by +2.52% compared to the previous week, the month change is a +34.07% rise, over the last year Xenon Pharmaceuticals has showed a +73.05% increase.
What is Xenon Pharmaceuticals market cap?▼
Today Xenon Pharmaceuticals has the market capitalization of 3.9B
When is the next Xenon Pharmaceuticals earnings date?▼
Xenon Pharmaceuticals is going to release the next earnings report on May 12, 2026.
What were Xenon Pharmaceuticals earnings last quarter?▼
XP0.F earnings for the last quarter are -1.11 EUR per share, whereas the estimation was -1.01 EUR resulting in a -9.94% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Xenon Pharmaceuticals revenue for the last year?▼
Xenon Pharmaceuticals revenue for the last year amounts to 13.32M EUR.
What is Xenon Pharmaceuticals net income for the last year?▼
XP0.F net income for the last year is -593.95M EUR.
How many employees does Xenon Pharmaceuticals have?▼
As of April 03, 2026, the company has 316 employees.
In which sector is Xenon Pharmaceuticals located?▼
Xenon Pharmaceuticals operates in the Health Care sector.
When did Xenon Pharmaceuticals complete a stock split?▼
Xenon Pharmaceuticals has not had any recent stock splits.
Where is Xenon Pharmaceuticals headquartered?▼
Xenon Pharmaceuticals is headquartered in Burnaby, CA.